Patients with a rare and aggressive form of prostate cancer showed improvement after treatment with a drug from BioXcel Therapeutics, the company reports.
A combination of BXCL701, BioXcel’s investigational oral innate immunity activator, and pembrolizumab showed strong clinical activity against metastatic castration-resistant prostate cancer in patients in a Phase 2 trial. The patients presented with either adenocarcinoma or small cell neuroendocrine carcinoma.